. Imprime PGG Binding in Healthy Donors can be Modified with Intravenous Immunoglobulin. IVIG, which contains high natural anti-β-glucan titers, can increase Imprime PGG binding to myeloid cells from a low-binder, in non-permissive conditions. Representative example of increasing Imprime PGG binding to low-binder neutrophils with IVIG is presented.
. Correlation of Imprime PGG Binding and IL-8 Production in WB from Healthy Donors. The amount of IL-8 in Imprime PGG (10 μg/ml) stimulated WB cultures are presented as fold increase over citrate control on the Y axis. Imprime PGG binding studies for all donors were performed on the same day of cytokine analysis. The mean IL-8 fold change values + SEM are presented for each group along the X axis. Differential Imprime PGG-Binding in Healthy Humans: Potential Predictive Biomarker Anti-b-glucan Abs can increase Imprime PGG binding on neutrophils and monocytes from a low-binder, in non-permissive conditions (low binder serum). Representative example of augmentation of Imprime PGG binding to low-binder neutrophils with anti-b-glucan Abs is presented.
Low-Binder PBMC Culture Supplemented with FRESH Serum

Anti-b Glucan
Imprime + High-binder Serum 
ABSTRACT OBJECTIVES
Imprime PGG ® (Imprime), is a soluble ß-1,3/1,6 immunomodulatory glucan, being developed in combination with monoclonal antibody therapy for multiple oncologic indications. To date, limited studies exist on the recognition and immunomodulatory activities of soluble glucans on the human immune system. Although yeast ß-glucans have been shown to be capable of binding human cells through leukocyte complement receptor 3 (CR3, Mac-1, αM ß2 integrin),
the key components for this event were not elucidated. Here, we demonstrate that Imprime, a soluble carbohydrate pathogen associated molecular pattern (PAMP), is recognized by only certain human cells expressing CR3 (i.e., bind to CR3-expressing myeloid cells, but not to CR3 expressing NK cells) and requires opsonization by complement components. Inactivation of serum complement components resulted in loss of binding and function. Surprisingly, not all healthy donor myeloid cells were capable of binding Imprime despite the presence of complement components. Looking into potential reasons for differential binding led to a strong correlation between being a high-Imprime binder and having a high-natural anti-ß glucan titer. Both, in vitro and in vivo feasibility studies in humans demonstrate the potential for converting a low-Imprime binder to a high-binder with anti-ß-glucan antibodies. Given the preclinical requirement for Imprime binding to myeloid cells for antitumor effects, we propose that assessing Imprime binding to blood immune cells could be a predictive biomarker, and enriching for high-binder patients or converting low-binders to high-binders by treating with high-titer plasma or IVIG, would enhance therapeutic efficacy.
• Determine the characteristics of Imprime PGG binding to immune subsets in human whole blood (WB)
• Correlate Imprime PGG binding to function
• Identify a predictive biomarker to screen for those patients with the highest potential to respond to Imprime PGG therapy in the clinic Figure 13 . Imprime PGG Induced IL-8 in Healthy WB can be Modified with Serum. Addition of high-binder (HB) serum to low-binder (LB) WB cells increases Imprime PGG's ability to not only bind, but also induce/enhance cytokine production. 
Preclinical MOA & Lessons from Translation
So far:
These in vitro human investigations have demonstrated the need for the following immune components for Imprime PGG binding and function:
• Complement Receptor 3 (CR3) • Complement • Anti-beta glucan antibodies Established significant correlation between Imprime PGG binding and function (e.g. cytokine production)
Demonstrated potential to augment Imprime PGG binding and function in "Low Binder" individuals with "High Binder" serum or intravenous Immunoglobulin containing natural anti-b glucan Abs
Next:
If the levels of natural anti-b glucan Abs in WB correlates with Imprime PGG binding and functional response in humans, there is a potential to incorporate this as a diagnostic screen in our clinical studies.
In vitro, high-PMN binders (>20% Imprime PGG binding) and high monocyte binders (<10% Imprime PGG binding) produce more IL-8 than low-binders IMPRIME PGG ® ß -glucans, Imprime PGG, was found to be capable of binding human myeloid cells in WB through complement receptor 3 (CR3). WB from some >30 healthy donors have been evaluated to date for Imprime PGG binding and here is a representative example of Imprime PGG binding to immune cells in a healthy donor's peripheral blood at 30 mins with 10ug/ml Imprime. On the top are cells treated with vehicle and the detection Ab and on the bottom are cells treated with Imprime PGG and the detection Ab. In this donor, Imprime bound to ~62% of the neutrophils, 36% of monocytes, 92% of B cells, 6% of the T cells and did not bind NK cells. These data are typical and representative of immune cell binding profile for healthy individuals who bind Imprime PGG in WB. Figure 4 . Cytokines Induced in WB Cultures by Imprime PGG. Healthy donor WB samples from multiple donors were stimulated overnight with Imprime PGG and evaluated for the presence of 26 different cytokines using the Luminex™ multi-analyte XMAP profiling technology (data not shown). Imprime PGG consistently induced only two chemokines, IL-8 and MCP-1. MIP-1ß and MIP-1α, were two other chemokines, although present in some donors at low levels, was variable. Proinflammatory cytokines (e.g., IL-1α, IL-6 and TNFα), induced by other known PAMP's (i.e. TLR7/8 agonist) were absent. A representative, smaller 5-plex data is presented.
Imprime PGG Binds to Innate Immune cells via Complement Receptor 3 (CR3)
Imprime PGG Binding to Immune Cell Subsets in Healthy Human Whole Blood
Correlation of Imprime PGG Binding to Function in Healthy Human Whole Blood
Ability of Serum/Plasma to Modify
Requirements for Imprime PGG Binding to Human Myeloid Cells in Whole Blood
Potential to Modify Imprime PGG Binding by Anti-ß -glucan Antibodies
Potential to Modify Imprime PGG Binding by Intravenous Immunoglobulin (IVIG) Modulation of Imprime PGG Binding on Myeloid Cells by IVIG is Serum-dependent
Differential Imprime PGG-Binding in Healthy Humans: Potential Predictive Biomarker Figure 5 . Requirements for Imprime PGG Binding to Human Myeloid Cells.
As demonstrated in the past, Imprime PGG bound to human neutrophils and monocytes only in the presence of normal (i.e. serum with intact complement) but not heat-inactivated, "complement deficient" serum. Likewise, Imprime PGG binding requires "CR3" and was not detected on CR3-blocked cells. Figure 9 . Imprime PGG Binding in Healthy Donors can be Modified with Plasma. Addition of high-binder plasma to a low-binder's WB cells increases Imprime PGG binding to myeloid cells converting a "low-binder" to a "high-binder". Fig -7A is a representative example of a "high" and "low" Imprime PGG neutrophil binder. B). Monocytes and PMNs utilize CR3 to bind Imprime PGG. Binding on both cell types for each healthy donor tested are presented in Fig 7B. High PMN binding (>20% binding) of Imprime PGG was found in ~35% of healthyvolunteers. Monocyte binding (>10% binding) of Imprime PGG parallels that of PMN binding in healthy volunteers. Anti-ß -glucan antibodies. Anti-ß-glucan Abs can increase Imprime PGG binding on neutrophils and monocytes from a low-binder, in non-permissive conditions (low binder serum). Representative example of augmentation of Imprime PGG binding to low-binder neutrophils with anti-ß-glucan Abs is presented. Figure 11 . Imprime PGG Binding in Healthy Donors can be Modified with Intravenous Immunoglobulin. IVIG, which contains high natural anti-ß-glucan titers, can increase Imprime PGG binding to myeloid cells from a low-binder, in non-permissive conditions. Representative example of increasing Imprime PGG binding to low-binder neutrophils with IVIG is presented. 
Potential to Modify Imprime PGG Function
using Serum or Plasma Figure 13 . Imprime PGG Induced IL-8 in Healthy WB can be Modified with Serum. Addition of high-binder (HB) serum to low-binder (LB) WB cells increases Imprime PGG's ability to not only bind, but also induce/ enhance cytokine production.
Figure 14. Potential to Modulate Imprime PGG induced Cytokine
Release with IVIG. A). IVIG dose response study, demonstrated 10 mg/ml of IVIG to be optimal concentration for use in combination with Imprime PGG in inducing an IL-8 functional response in most donors tested. Representative data from a low-binder and high-binder presented. B). IVIG, which contains natural antiß-glucan antibodies, increased Imprime PGG induced cytokine production from a low-binder, in non-permissive conditions. Differential Imprime PGG Binding in Healthy Humans
